"ESMO 2025: MSD’s ADC leapfrogs to Phase III in colorectal cancer " was originally created and published by Clinical Trials ...

MSD and Eisai presented the data at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany. The ...

Discover the features and functionalities of the ROCCAT Kone XTD Gaming Mouse in our comprehensive software overview. This ...

BERLIN -- Antibody-drug conjugates (ADCs) targeting Trop2 made a strong case as first-line standard of care for metastatic ...

Imagine an assembly line where each tool monitors how it’s used; errors are detected before they occur; and digital work ...

MSD's cancer immunotherapy Keytruda will soon be available as a subcutaneous injection that does away with the need to visit an infusion clinic. Keytruda Qlex (pembrolizumab and berahyaluronidase alfa ...

MSD has moved a step closer to completing its acquisition of Verona Pharma, after a vote in favour of the transaction by the UK company's shareholders. Investors in Verona – a specialist in ...

Tricking cancer cells into self-destructing could reduce risk of recurrence and death in colon cancer by 50%. Results also ...